Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 13 to 17 years.
Chemotherapy Induced Nausea and Vomiting
DRUG: granisetron transdermal system|DRUG: Granisetron IV
Plasma concentration, Analysis of the plasma concentration of Intravenous granisetron vs transdermal granisetron in pediatric patients receiving chemotherapy over two sequential cycles., Up to 7 days
Chang is Safety from baseline, Safety: based on medical review of adverse event reports and the results of vital sign measurements, electrocardiograms (ECGs), Up to 7 days
The purpose of this study is to determine the dosing strategy for adolescents aged 13 to 17 years.